This randomized phase II study aims to investigate whether the addition of bevacizumab to
standard corticosteroid therapy results in greater improvement in symptoms and less
treatment-induced symptoms compared with standard corticosteroid therapy for patients with
symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition
of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and
improve neurologic impairments in patients with brain radionecrosis following radiosurgery
for brain metastases.
Radionecrosis, Brain Metastases